geographic atrophy

News

Astellas cuts $5.9bn deal to buy Iveric Bio

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,

News

Complement raises €72m for geographic atrophy gene therapy

UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing

News

Apellis breaks new ground in geographic atrophy

Syfovre is the first FDA-approved drug for GA, which damages the sight of 5m people worldwide.

Views & Analysis

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Last month, pharmaphorum spoke with Dr Charles C.

News

Longer-term data raise prospects for Apellis' pegcetacoplan

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Novartis adds gene therapy for blindness with Gyroscope buy

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect.

Astellas cuts $5.9bn deal to buy Iveric Bio

Complement raises €72m for geographic atrophy gene therapy

Apellis breaks new ground in geographic atrophy

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Longer-term data raise prospects for Apellis' pegcetacoplan

Novartis adds gene therapy for blindness with Gyroscope buy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

geographic atrophy

Editor's Picks